COMPARISON
Exenatide vs Glucagon
6 attributes held for at least one of the two. 6 differ. Each value carries the register it came from and the date that register was read.
Answer
Exenatide is authorised or registered in 5 and Glucagon in 10 of the 10 registers read. Exenatide: highest phase Phase 2. Glucagon: highest phase Phase 4 (after approval). 83 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Exenatide | Glucagon | |
|---|---|---|
| Registered trials differs | 383 clinicaltrials.gov · 2026-10-03 | 1514 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Byetta openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Glucagon openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Withdrawn ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | Not checked no record of "authorisedOn" for exenatide | 2019-12-16 ema · 2026-10-03 |
| EU withdrawn on differs | 2024-11-20 ema · 2026-10-03 | Not checked no record of "withdrawnOn" for glucagon |
| ATC code differs | A10BJ01 ema · 2026-10-03 | H04AA01 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Exenatide | placebo | Glucagon | placebo |
|---|---|---|---|---|
| Headache | 1.9% | 1.3% | - | - |
| Non-cardiac chest pain | 1.1% | 1.0% | - | - |
| Osteoarthritis | 0.9% | 1.0% | - | - |
| Dizziness | 0.8% | 0.4% | - | - |
| Constipation | 0.8% | 0.3% | - | - |
| Dyspepsia | 0.8% | 0.3% | - | - |
| Chronic obstructive pulmonary disease | 0.7% | 0.7% | - | - |
| Fatigue | 0.6% | 0.1% | - | - |
| Back pain | 0.5% | 0.6% | - | - |
| Sinusitis | 0.5% | 0.2% | - | - |
Trial register Exenatide: 24 placebo-controlled trials; Glucagon: 2. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Exenatide side effects · Glucagon side effects
LEGAL STATUS
Approval in each country read
| Country | Exenatide | Glucagon | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Withdrawn | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Status unknown | Registered | TGA |
| Switzerland | Not on the register | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Not on the register | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
83 registered trials include both
| NCT05663515 | A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Init RECRUITING · updated 2026-09-24 |
|---|---|
| NCT06725693 | Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease RECRUITING · updated 2026-09-08 |
| NCT05220917 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study ACTIVE_NOT_RECRUITING · updated 2026-08-13 |
| NCT07702461 | Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists RECRUITING · updated 2026-07-24 |
| NCT07497399 | Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis RECRUITING · updated 2026-07-17 |
| NCT02860923 | Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy COMPLETED · updated 2026-05-22 |
| NCT04520490 | Brain Activation and Satiety in Children 2 ACTIVE_NOT_RECRUITING · updated 2026-01-05 |
| NCT07309094 | Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD RECRUITING · updated 2025-12-30 |
| NCT05073692 | Comparison of Type 2 Diabetes Pharmacotherapy Regimens COMPLETED · updated 2025-11-21 |
| NCT05670379 | Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant COMPLETED · updated 2025-09-23 |
| NCT05762744 | Pharmacogenomics of GLP1 Receptor Agonists TERMINATED · updated 2025-07-01 |
| NCT03492580 | A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants COMPLETED · updated 2025-06-25 |
| NCT06888167 | Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function. RECRUITING · updated 2025-03-21 |
| NCT05662189 | Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus RECRUITING · updated 2025-03-18 |
| NCT04307797 | Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes COMPLETED · updated 2024-09-19 |
| NCT02673931 | GLP-1 and Hyperoxia for Organ Protection in Heart Surgery UNKNOWN · updated 2024-08-28 |
| NCT06449235 | Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh UNKNOWN · updated 2024-07-16 |
| NCT03835013 | Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers COMPLETED · updated 2024-04-03 |
| NCT01524705 | FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) COMPLETED · updated 2023-12-29 |
| NCT04504370 | Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects COMPLETED · updated 2023-07-28 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.